Download PDF
Semin Respir Crit Care Med 2019; 40(02): 173-183
DOI: 10.1055/s-0039-1685214
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pulmonary Hypertension Associated with Connective Tissue Disease

Hossam Fayed
1   Pulmonary Hypertension Unit, Royal Free Hospital, London, United Kingdom
,
J. Gerry Coghlan
1   Pulmonary Hypertension Unit, Royal Free Hospital, London, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2019 (online)

    Permissions and Reprints

Abstract

Pulmonary hypertension (PH) is common in most forms of connective tissue disease (CTD); the prevalent type of PH depends on the particular CTD. Thus, pulmonary arterial hypertension (PAH) is dominantly associated with scleroderma, while postcapillary PH is most common in rheumatoid arthritis and lung disease-associated PH is typically found in myositis and sarcoidosis.

Considerable expertise is required to identify, diagnose, and manage CTD-PH, as the primary physicians providing the majority of care for this population, rheumatologists, need a good working knowledge of CTD-PH, its rather subtle presentation, and how to access the necessary investigations to screen for and identify patients with PH. The role of the rheumatologist does not stop at diagnosis; in some conditions such as lupus, optimizing immunosuppression is key to the management of PH, and unlike simple idiopathic PAH, the natural history of CTD-PH is often punctuated by complications of the CTD rather than just events due to progression of PH or therapy-related adverse events.

The aim of this article is to provide an overview of all forms of CTD-PH, and to provide an easy reference source on current best practice.

Keywords

pulmonary hypertension - pulmonary arterial hypertension - screening - WHO group - risk assessment tools - NTproBNP - SSc PAH
 

  • References

  • 1 Galiè N, Humbert M, Vachiery JL. , et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903-975
    CrossrefPubMedGoogle Scholar
  • 2 NHS Digital. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/national-pulmonary-hypertension-audit/2018/2018 . Accessed March 18, 2019
    PubMed
  • 3 Nicola PJ, Maradit-Kremers H, Roger VL. , et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005; 52 (02) 412-420
    CrossrefPubMedGoogle Scholar
  • 4 Coghlan JG, Schreiber B, D'Cruz D. The heart in rheumatic disease. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Wiseman MH. , eds. Rheumatology. 6th ed. Philadelphia, PA: Elsevier; 2015: 267-273
    Google Scholar
  • 5 Simonneau G, Montani D, Celermajer DS. , et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53 (01) 1801913
    CrossrefPubMedGoogle Scholar
  • 6 Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34 (04) 888-894
    CrossrefPubMedGoogle Scholar
  • 7 Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum 2013; 65 (04) 1074-1084
    CrossrefPubMedGoogle Scholar
  • 8 Coghlan JG, Wolf M, Distler O. , et al. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 2018; 51 (04) 1701197
    CrossrefPubMedGoogle Scholar
  • 9 Taboada D, Pepke-Zaba J, Jenkins DP. , et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J 2014; 44 (06) 1635-1645
    CrossrefPubMedGoogle Scholar
  • 10 Coghlan JG, Denton CP, Grünig E. , et al; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73 (07) 1340-1349
    CrossrefPubMedGoogle Scholar
  • 11 Visovatti SH, Distler O, Coghlan JG. , et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther 2014; 16 (06) 493
    CrossrefPubMedGoogle Scholar
  • 12 Vachiéry JL, Tedford RJ, Rosenkranz S. , et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53 (01) 1801897
    CrossrefPubMedGoogle Scholar
  • 13 Nathan SD, Barbera JA, Gaine SP. , et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53 (01) 1801914
    CrossrefPubMedGoogle Scholar
  • 14 Schreiber BE, Valerio CJ, Keir GJ. , et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum 2011; 63 (11) 3531-3539
    CrossrefPubMedGoogle Scholar
  • 15 Frost A, Badesch D, Gibbs JSR. , et al. Diagnosis of pulmonary hypertension. Eur Respir J 2019; 53 (01) 1801904
    CrossrefPubMedGoogle Scholar
  • 16 Bissell LA, Anderson M, Burgess M. , et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology (Oxford) 2017; 56 (06) 912-921
    CrossrefPubMedGoogle Scholar
  • 17 Huang D, Cheng YY, Chan PH. , et al. Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study. ERJ Open Res 2018; 4 (01) 00135-02017
    PubMedGoogle Scholar
  • 18 Vonk MC, Broers B, Heijdra YF. , et al. Systemic sclerosis and its pulmonary complications in the Netherlands: an epidemiological study. Ann Rheum Dis 2009; 68 (06) 961-965
    CrossrefPubMedGoogle Scholar
  • 19 Avouac J, Airò P, Meune C. , et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37 (11) 2290-2298
    CrossrefPubMedGoogle Scholar
  • 20 Nihtyanova SI, Schreiber BE, Ong VH. , et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66 (06) 1625-1635
    CrossrefPubMedGoogle Scholar
  • 21 Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S. ; Australian Scleroderma Interest Group (ASIG). Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Res Ther 2017; 19 (01) 42
    CrossrefPubMedGoogle Scholar
  • 22 Hachulla E, Gressin V, Guillevin L. , et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52 (12) 3792-3800
    CrossrefPubMedGoogle Scholar
  • 23 Condliffe R, Kiely DG, Peacock AJ. , et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179 (02) 151-157
    CrossrefPubMedGoogle Scholar
  • 24 Gordon C, Amissah-Arthur MB, Gayed M. , et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018; 57 (01) 14-18
    CrossrefPubMedGoogle Scholar
  • 25 Hachulla E, Jais X, Cinquetti G. , et al; French Collaborators Recruiting Members. Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French Pulmonary Hypertension Registry. Chest 2018; 153 (01) 143-151
    CrossrefPubMedGoogle Scholar
  • 26 Chung L, Liu J, Parsons L. , et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138 (06) 1383-1394
    CrossrefPubMedGoogle Scholar
  • 27 Sobanski V, Giovannelli J, Lynch BM. , et al. Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol 2016; 68 (02) 484-493
    PubMedGoogle Scholar
  • 28 Montani D, Henry J, O'Connell C. , et al. Association between rheumatoid arthritis and pulmonary hypertension: data from the French Pulmonary Hypertension Registry. Respiration 2018; 95 (04) 244-250
    CrossrefPubMedGoogle Scholar
  • 29 Yang X, Mardekian J, Sanders KN, Mychaskiw MA, Thomas III J. Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol 2013; 32 (10) 1519-1531
    CrossrefPubMedGoogle Scholar
  • 30 Fox BD, Shimony A, Langleben D. , et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 2013; 42 (04) 1083-1091
    CrossrefPubMedGoogle Scholar
  • 31 Günther S, Jaïs X, Maitre S. , et al. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012; 64 (09) 2995-3005
    CrossrefPubMedGoogle Scholar
  • 32 Hachulla AL, Launay D, Gaxotte V. , et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68 (12) 1878-1884
    CrossrefPubMedGoogle Scholar
  • 33 Connolly MJ, Abdullah S, Ridout DA, Schreiber BE, Haddock JA, Coghlan JG. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension. Rheumatology (Oxford) 2017; 56 (12) 2197-2203
    CrossrefPubMedGoogle Scholar
  • 34 Goh NS, Desai SR, Veeraraghavan S. , et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177 (11) 1248-1254
    CrossrefPubMedGoogle Scholar
  • 35 Antoniou KM, Margaritopoulos GA, Goh NS. , et al. Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheumatol 2016; 68 (04) 1004-1012
    PubMedGoogle Scholar
  • 36 Olsson KM, Delcroix M, Ghofrani HA. , et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129 (01) 57-65
    CrossrefPubMedGoogle Scholar
  • 37 Khan MS, Usman MS, Siddiqi TJ. , et al. Is anticoagulation beneficial in pulmonary arterial hypertension?. Circ Cardiovasc Qual Outcomes 2018; 11 (09) e004757
    PubMedGoogle Scholar
  • 38 Masa JF, Corral J, Caballero C. , et al; Spanish Sleep Network. Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax 2016; 71 (10) 899-906
    CrossrefPubMedGoogle Scholar
  • 39 Hoeper M, Benza RL, Corris P. , et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J 2019 53. (01). pii: 1801906. (e-pub ahead of print). Doi: 10.1183/13993003.01906-2018
    PubMedGoogle Scholar
  • 40 Price LC, Dimopoulos K, Marino P. , et al. The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. Thorax 2017; 72 (11) 1035-1045
    CrossrefPubMedGoogle Scholar
  • 41 Rhee RL, Gabler NB, Praestgaard A, Merkel PA, Kawut SM. Adverse events in connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol 2015; 67 (09) 2457-2465
    PubMedGoogle Scholar
  • 42 Rhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM. Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192 (09) 1111-1117
    CrossrefPubMedGoogle Scholar
  • 43 Coghlan JG, Denton CP. Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension. J Scleroderma Relat Disord 2018; 3 (01) 30-38
    PubMedGoogle Scholar
  • 44 Coghlan JG, Channick R, Chin K. , et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON Study. Am J Cardiovasc Drugs 2018; 18 (01) 37-47
    CrossrefPubMedGoogle Scholar
  • 45 Coghlan JG, Galiè N, Barberà JA. , et al; AMBITION investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017; 76 (07) 1219-1227
    CrossrefPubMedGoogle Scholar
  • 46 Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. Nat Rev Rheumatol 2018; 14 (09) 511-527
    CrossrefPubMedGoogle Scholar
  • 47 Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol 2012; 2012: 854941
    PubMedGoogle Scholar
  • 48 Badesch DB, Raskob GE, Elliott CG. , et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137 (02) 376-387
    CrossrefPubMedGoogle Scholar
  • 49 Humbert M, Sitbon O, Chaouat A. , et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173 (09) 1023-1030
    CrossrefPubMedGoogle Scholar
  • 50 Mercurio V, Diab N, Peloquin G. , et al. Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model. Eur Respir J 2018; 52 (04) 1800497
    CrossrefPubMedGoogle Scholar
  • 51 Mavrogeni S, Gialafos E, Karabela G, Stavropoulos E, Sfendouraki E, Kolovou G. “The silence of lambs”: Cardiac lesions in asymptomatic immune-mediated diseases detected by cardiovascular magnetic resonance. Int J Cardiol 2013; 168 (03) 2901-2902
    CrossrefPubMedGoogle Scholar
  • 52 Tejeda-Maldonado J, Quintanilla-González L, Galindo-Uribe J, Hinojosa-Azaola A. Cardiac surgery in systemic lupus erythematosus patients: clinical characteristics and outcomes. Reumatol Clin 2018; 14 (05) 269-277
    CrossrefPubMedGoogle Scholar
  • 53 de Groote P, Gressin V, Hachulla E. , et al; ItinerAIR-Scleroderma Investigators. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67 (01) 31-36
    CrossrefPubMedGoogle Scholar
  • 54 Burkard T, Trendelenburg M, Daikeler T. , et al. The heart in systemic lupus erythematosus - A comprehensive approach by cardiovascular magnetic resonance tomography. PLoS One 2018; 13 (10) e0202105
    CrossrefPubMedGoogle Scholar
  • 55 Cereda AF, Pedrotti P, De Capitani L, Giannattasio C, Roghi A. Comprehensive evaluation of cardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) with cardiac magnetic resonance. Eur J Intern Med 2017; 39: 51-56
    CrossrefPubMedGoogle Scholar
  • 56 Pieroni M, De Santis M, Zizzo G. , et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 2014; 43 (04) 526-535
    CrossrefPubMedGoogle Scholar
  • 57 Van Aelst LN, Čelutkienė J, Mebazaa A. Advanced heart failure: look right to prognosticate right!. Eur J Heart Fail 2016; 18 (05) 573-575
    CrossrefPubMedGoogle Scholar
  • 58 Priori SG, Blomström-Lundqvist C, Mazzanti A. , et al; Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace 2015; 17 (11) 1601-1687
    PubMedGoogle Scholar
  • 59 Hulten E, Agarwal V, Cahill M. , et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging 2016; 9 (09) e005001
    PubMedGoogle Scholar
  • 60 De Luca G, Bosello SL, Gabrielli FA. , et al. Prognostic role of ventricular ectopic beats in systemic sclerosis: a prospective cohort study shows ECG indexes predicting the worse outcome. PLoS One 2016; 11 (04) e0153012
    CrossrefPubMedGoogle Scholar
  • 61 Ponikowski P, Voors AA, Anker SD. , et al; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18 (08) 891-975
    CrossrefPubMedGoogle Scholar
  • 62 Costanzo MR, Stevenson LW, Adamson PB. , et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. JACC Heart Fail 2016; 4 (05) 333-344
    CrossrefPubMedGoogle Scholar
  • 63 Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest 2013; 144 (01) 169-176
    CrossrefPubMedGoogle Scholar
  • 64 Raghu G, Behr J, Brown KK. , et al; ARTEMIS-IPF Investigators*. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158 (09) 641-649
    CrossrefPubMedGoogle Scholar
  • 65 Nathan SD, Behr J, Collard HR. , et al. RISE-IIP: riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia. Eur Respir J 2017; 50: OA1985
    PubMedGoogle Scholar
  • 66 Corte TJ, Keir GJ, Dimopoulos K. , et al; BPHIT Study Group. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2014; 190 (02) 208-217
    CrossrefPubMedGoogle Scholar
  • 67 Volkmann ER, Saggar R, Khanna D. , et al. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol 2014; 66 (07) 1900-1908
    PubMedGoogle Scholar
  • 68 Kim N, Delcroix M, Jais X. , et al. Chronic thromboembolic pulmonary hypertension. Euro Respir J 2019 53. (01). pii: 1801915. (e-pub ahead of print). Doi: 10.1183/13993003.01915-2018
    PubMedGoogle Scholar
  • 69 Ley S, Ley-Zaporozhan J, Pitton MB. , et al. Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2012; 22 (03) 607-616
    CrossrefPubMedGoogle Scholar
  • 70 Kim E, Do T, Peacock K, Takundwa PT. Recommended therapeutic INR range for patients with antiphospholipid syndrome on warfarin anticoagulation: is moderate-intensity (INR 2.0 - 3.0) or high-Intensity (INR 3.1 - 4.0) better for reducing risk of recurrent thromboembolic events?. Cureus 2016; 8 (09) e765
    PubMedGoogle Scholar
  • 71 Ghofrani HA, D'Armini AM, Grimminger F. , et al; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369 (04) 319-329
    CrossrefPubMedGoogle Scholar
  • 72 Ghofrani HA, Simonneau G, D'Armini AM. , et al; MERIT study investigators. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med 2017; 5 (10) 785-794
    CrossrefPubMedGoogle Scholar
  • 73 Lang I, Meyer BC, Ogo T. , et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26 (143) 160119
    CrossrefPubMedGoogle Scholar
  • 74 Montani D, Achouh L, Dorfmüller P. , et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87 (04) 220-233
    PubMedGoogle Scholar
  • 75 Montani D, Girerd B, Jaïs X. , et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017; 5 (02) 125-134
    CrossrefPubMedGoogle Scholar